Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $19.9375.
A number of analysts have issued reports on the company. JPMorgan Chase & Co. raised their price target on Roivant Sciences from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Thursday, September 18th. Weiss Ratings restated a "sell (d+)" rating on shares of Roivant Sciences in a report on Wednesday, October 8th. Citigroup initiated coverage on Roivant Sciences in a report on Tuesday, September 2nd. They issued a "buy" rating and a $16.00 price target for the company. Leerink Partners boosted their price objective on Roivant Sciences from $18.00 to $22.00 and gave the company an "outperform" rating in a research report on Thursday, September 18th. Finally, Jefferies Financial Group boosted their price objective on Roivant Sciences from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, September 18th.
Get Our Latest Research Report on Roivant Sciences
Insider Buying and Selling at Roivant Sciences
In other news, CEO Eric Venker sold 118,418 shares of the company's stock in a transaction on Friday, October 17th. The stock was sold at an average price of $17.06, for a total value of $2,020,211.08. Following the completion of the sale, the chief executive officer owned 1,504,959 shares in the company, valued at $25,674,600.54. This represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold a total of 5,228,958 shares of company stock valued at $76,447,638 in the last ninety days. Corporate insiders own 10.80% of the company's stock.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of ROIV. GAMMA Investing LLC raised its position in Roivant Sciences by 83.0% during the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company's stock valued at $66,000 after buying an additional 2,945 shares during the period. Penn Davis Mcfarland Inc. grew its stake in Roivant Sciences by 3.5% in the first quarter. Penn Davis Mcfarland Inc. now owns 1,707,232 shares of the company's stock valued at $17,226,000 after purchasing an additional 58,206 shares in the last quarter. GF Fund Management CO. LTD. grew its stake in Roivant Sciences by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 18,641 shares of the company's stock valued at $188,000 after purchasing an additional 3,356 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Roivant Sciences by 16.3% in the first quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company's stock valued at $40,362,000 after purchasing an additional 560,641 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Roivant Sciences by 10.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 102,478 shares of the company's stock valued at $1,034,000 after purchasing an additional 9,357 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.
Roivant Sciences Stock Up 0.7%
Shares of ROIV stock opened at $17.87 on Wednesday. The stock has a market cap of $12.20 billion, a P/E ratio of -25.53 and a beta of 1.20. Roivant Sciences has a fifty-two week low of $8.73 and a fifty-two week high of $18.06. The business has a fifty day simple moving average of $14.23 and a 200-day simple moving average of $12.13.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
